Evofem Biosciences Inc
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
EVFM$0.48-23.4%Stored close · as of Aug 10, 2022
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Three months ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(4,809) | $(2,354) |
| Adjustments to reconcile net loss to net cash, cash equivalents and restricted cash provided by (used in) operating activities: | ||
| Loss on issuance of financial instruments | 3,275 | 84 |
| Change in fair value of financial instruments | (802) | (1,612) |
| Gain on debt extinguishment | (1,120) | - |
| Stock-based compensation | 237 | 417 |
| Depreciation | 12 | 245 |
| Noncash interest expense | 564 | 565 |
| Noncash right-of-use amortization | 47 | 504 |
| Net loss on disposal of property and equipment | 5 | - |
| Changes in operating assets and liabilities: | ||
| Trade accounts receivable | 1,432 | (6,278) |
| Inventories | 391 | (99) |
| Prepaid and other assets | 573 | 1,518 |
| Accounts payable | (726) | 3,813 |
| Accrued expenses and other liabilities | 438 | (352) |
| Accrued compensation | 652 | (800) |
| Operating lease liabilities | (46) | (591) |
| Net cash and restricted cash provided by (used in) operating activities | 123 | (4,940) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (14) | (3) |
| Net cash and restricted cash used in investing activities | (14) | (3) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock - exercise of warrants | - | 61 |
| Borrowings under term notes | - | 1,640 |
| Net cash and restricted cash provided by financing activities | - | 1,701 |
| Net change in cash, cash equivalents and restricted cash | 109 | (3,242) |
| Cash, cash equivalents and restricted cash, beginning of period | 580 | 4,776 |
| Cash, cash equivalents and restricted cash, end of period | $689 | $1,534 |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Issuance of common stock upon exercise of purchase rights | 89 | 180 |
| Purchases of property and equipment included in accounts payable and accrued expenses | 78 | 140 |
| Series E-1 shares deemed dividends | 47 | - |
| Issuance of common stock upon conversion of notes | 35 | - |
| Issuance of common stock upon exercise of warrants | 15 | - |
| Financing costs included in accounts payable and accrued expenses | - | 125 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.